Moderna Inc (MRNA)vsNanobiotix (NBTX)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NBTX
Nanobiotix
$37.01
-1.57%
HEALTHCARE · Cap: $1.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 6736% more annual revenue ($2.23B vs $32.59M). NBTX leads profitability with a -73.5% profit margin vs -141.4%. NBTX earns a higher WallStSmart Score of 22/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NBTX
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NBTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Revenue surging 186.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -198.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NBTX
The strongest argument for NBTX centers on Revenue Growth, Debt/Equity. Revenue growth of 186.8% demonstrates continued momentum.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NBTX
The primary concerns for NBTX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NBTX is a hypergrowth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
NBTX is growing revenue faster at 186.8% — sustainability is the question.
NBTX generates stronger free cash flow (-16M), providing more financial flexibility.
Bottom Line
NBTX scores higher overall (22/100 vs 21/100) and 186.8% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nanobiotix
HEALTHCARE · BIOTECHNOLOGY · USA
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?